vimarsana.com
Home
Live Updates
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow : vimarsana.com
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow : vimarsana.com
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...
Related Keywords
Japan ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Canada ,
Jerusalem ,
Israel General ,
Israel ,
Daiichi Sankyo ,
Trastuzumab Deruxtecan ,
Capecitabine Monotherapy ,
End Results Program ,
Merck Co Inc ,
National Cancer Institute ,
Astrazeneca ,
Daiichi Sankyo Inc ,
Low Metastatic Breast Cancer ,
Solid Tumors ,
Positive Locally Advanced ,
Metastatic Gastric Cancer ,
Positive Metastatic Breast ,
Low Metastatic Breast ,
Mutant Unresectable ,
Metastatic Solid ,
Reproductive Potential ,
Hepatic Impairment ,
Prescribing Information ,
Rare Diseases ,
Cancer Res ,
Plus Exemestane ,
Estrogen Receptor ,
Negative Advanced Breast ,
End Results ,
Accessed April ,
Epidermal Growth Factor Receptor ,
Mol Biol ,
Pathol Transl ,
Previously Treated ,
Low Advanced Breast ,
Markets ,